Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation (ROXI-EVEREST)

November 17, 2026 updated by: Regeneron Pharmaceuticals

A Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention With REGN7508, a Monoclonal Antibody Against Factor XI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-EVEREST)

This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.

The aim of the study is to see how safe and effective REGN7508 is in preventing stroke and/or systemic embolism in participants with atrial fibrillation and how it compares against participants that will receive apixaban in this study.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

15364

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Longueuil, Canada, J4H4B9
        • Recruiting
        • Viacar Recherches Cliniques inc.
    • Ontario
      • Hamilton, Ontario, Canada, L8L 5G4
        • Recruiting
        • Premiere Clinical Trial Network
      • Scarborough Village, Ontario, Canada, M1B 4Z8
        • Recruiting
        • Heart Health Institute Research Inc.
    • Quebec
      • Sherbrooke, Quebec, Canada, J1LOK3
        • Recruiting
        • Diex Recherche Inc.
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 466-8650
        • Recruiting
        • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
    • Ehime
      • Uwajima, Ehime, Japan, 798-8510
        • Recruiting
        • Uwajima City Hospital
    • Fukuoka
      • Onga District, Fukuoka, Japan, 811-4342
        • Recruiting
        • Onga Nakama Medical Association Onga Hospital
    • Gifu
      • Gifu, Gifu, Japan, 500-8717
        • Recruiting
        • Gifu Prefectural General Medical Center - Main Hospital Building
    • Hokkaido
      • Sapporo, Hokkaido, Japan, 062-0003
        • Recruiting
        • Hanaoka Seishu Memorial Hospital
    • Hyōgo
      • Kawanishi, Hyōgo, Japan, 666-0125
        • Recruiting
        • The Veritas Hospital
    • Ibaraki
      • Higashiibaraki District, Ibaraki, Japan, 311-3193
        • Recruiting
        • National Hospital Organization Mito Medical Center
      • Tsuchiura, Ibaraki, Japan, 300-8585
        • Recruiting
        • National Hospital Organization Kasumigaura Medical Center
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 234-0054
        • Recruiting
        • Saiseikai Yokohama-shi Nanbu Hospital
    • Kyoto
      • Kyoto, Kyoto, Japan, 607-8062
        • Recruiting
        • Rakuwakai Otowa Hospital
    • Shizuoka
      • Shizuoka, Shizuoka, Japan, 420-8630
        • Recruiting
        • Shizuoka City Shizuoka Hospital, East Building
    • Tokyo
      • Hachiōji, Tokyo, Japan, 192-0918
        • Recruiting
        • Minamino Cardiovascular Hospital
      • Suginami Ward, Tokyo, Japan, 168-0065
        • Recruiting
        • NewHeart Watanabe International Hospital
    • Yokohama-shi
      • Kanagawa, Yokohama-shi, Japan, 247-0005
        • Recruiting
        • JA Tsuchiura Kyodo General Hospital
    • Alabama
      • Alexander City, Alabama, United States, 35010
        • Recruiting
        • Advanced Cardiovascular
      • Dothan, Alabama, United States, 36305
        • Recruiting
        • SEC Clinical Research
      • Fairhope, Alabama, United States, 36532
        • Recruiting
        • Eastern Shore Research Institute
    • Arizona
      • Glendale, Arizona, United States, 85306
        • Recruiting
        • West Valley Clinical Trials
      • Scottsdale, Arizona, United States, 85260
        • Recruiting
        • Scottsdale Clinical Trials
    • Arkansas
      • Little Rock, Arkansas, United States, 72205
        • Recruiting
        • Arkansas Cardiology P.A.
    • California
      • Covina, California, United States, 91723
        • Recruiting
        • Valley Clinical Trials, Inc
      • Fremont, California, United States, 94538
        • Recruiting
        • Mission Cardiovascular Research Institute
      • Huntington Beach, California, United States, 92648
        • Recruiting
        • National Institute of California Heart and Vein Specialists
      • Inglewood, California, United States, 90301
        • Recruiting
        • Alliance Clinical Los Angeles
      • La Jolla, California, United States, 92037
        • Recruiting
        • Profound Research LLC at San Diego Cardiovascular Associates
      • Newport Beach, California, United States, 92663
        • Recruiting
        • Radin Cardiovascular Medical Group
      • Northridge, California, United States, 91325
        • Recruiting
        • Valley Clinical Trials, LLC dba Flourish Research
      • Pasadena, California, United States, 91105
        • Recruiting
        • Southern California Heart Specialists
      • Redding, California, United States, 96001
        • Recruiting
        • The Cardiovascular Center
      • Santa Maria, California, United States, 93454
        • Recruiting
        • FOMAT - Comprehensive Cardiovascular Care
      • Ventura, California, United States, 93003
        • Recruiting
        • Cardiology Associates Medical Group
      • West Hills, California, United States, 91307
        • Recruiting
        • Interventional Cardiology Medical Group
    • Florida
      • Boca Raton, Florida, United States, 33434
        • Recruiting
        • Excel Medical Clinical Trials, dba Flourish Research
      • Cutler Bay, Florida, United States, 33189
        • Recruiting
        • Nouvelle Clinical Research LLC
      • Inverness, Florida, United States, 34452
        • Recruiting
        • Nature Coast Clinical Research - Inverness
      • Jacksonville, Florida, United States, 32216
        • Recruiting
        • East Coast Institute for Research, Jacksonville
      • Medley, Florida, United States, 33166
        • Recruiting
        • South Florida Research Organization LLC
      • Miami, Florida, United States, 33135
        • Recruiting
        • Novera Clinical Research
      • New Smyrna Beach, Florida, United States, 32168
        • Recruiting
        • Healix Clinical Research
      • Pensacola, Florida, United States, 32503
        • Recruiting
        • Sec Clinical Research
      • Saint Augustine, Florida, United States, 32086
        • Recruiting
        • Flourish Research, St. Johns Center for Clinical Research
      • Saint Augustine, Florida, United States, 32086
        • Recruiting
        • East Coast Institute for Research, St. Augustine
      • Sarasota, Florida, United States, 34239
        • Recruiting
        • Cardiovascular Center of Sarasota Foundation for Research and Education
      • Winter Park, Florida, United States, 32789
        • Recruiting
        • Clinical Site Partners, LLC DBA Flourish Research
    • Georgia
      • Atlanta, Georgia, United States, 30342
        • Recruiting
        • Atlanta Clinical Research Centers
      • Atlanta, Georgia, United States, 30310
        • Recruiting
        • Morehouse School Of Medicine
      • Johns Creek, Georgia, United States, 30024
        • Recruiting
        • NSC Research, Inc
    • Indiana
      • Hobart, Indiana, United States, 46342
        • Recruiting
        • Profound Research, Advanced Cardiovascular Care + Electrophysiology Clinic
      • Indianapolis, Indiana, United States, 46237
        • Recruiting
        • Franciscan Physician Network, Indiana Heart Physicians
      • Munster, Indiana, United States, 46321
        • Recruiting
        • Profound Research, Powers Health Medical Group - Electrophysiology
      • Munster, Indiana, United States, 46321-4054
        • Recruiting
        • Cardiovascular Research of Northwest Indiana, LLC
    • Louisiana
      • West Monroe, Louisiana, United States, 71291
        • Recruiting
        • Monroe Research, LLC
    • Maryland
      • Ft. Washington, Maryland, United States, 20744
        • Recruiting
        • Anderson Medical Research
    • Massachusetts
      • Foxborough, Massachusetts, United States, 02035
        • Recruiting
        • K2 Medical Research, Foxboro
    • Michigan
      • Bloomfield Hills, Michigan, United States, 48304
        • Recruiting
        • Profound Research, Cardiology and Vascular Associates (CAVA) - Bloomfield Hills
      • Farmington Hills, Michigan, United States, 48334
        • Recruiting
        • Profound Research, Millennium Cardiology
      • Flint, Michigan, United States, 48503
        • Recruiting
        • Flint Clinical Research
      • Flint, Michigan, United States, 48504
        • Recruiting
        • AA Medical Research Center (MRC)
    • New York
      • Staten Island, New York, United States, 10309
        • Recruiting
        • Super Health Pharmacy
    • North Carolina
      • Concord, North Carolina, United States, 28025
        • Recruiting
        • Hawthorne Health, Moose Pharmacy of Concord
      • High Point, North Carolina, United States, 27260
        • Recruiting
        • Peters Medical Research
    • North Dakota
      • Fargo, North Dakota, United States, 58104
        • Recruiting
        • Lillestol Research LLC
    • Ohio
      • Marion, Ohio, United States, 43302
        • Recruiting
        • K&R Research LLC
      • Maumee, Ohio, United States, 43537
        • Recruiting
        • Advanced Medical Research
    • South Dakota
      • Rapid City, South Dakota, United States, 57701
        • Recruiting
        • Monument Health Clinical Research
    • Tennessee
      • Knoxville, Tennessee, United States, 37912
        • Recruiting
        • Norwood Family Medicine
      • Tullahoma, Tennessee, United States, 37388
        • Recruiting
        • Tennessee Center for Clinical Trials
    • Texas
      • Amarillo, Texas, United States, 79106
        • Recruiting
        • PharmaTex Research
      • Brownsville, Texas, United States, 78520
        • Recruiting
        • PanAmerican Clinical Research
      • Houston, Texas, United States, 77061
        • Recruiting
        • Synergy Groups Medical
      • Houston, Texas, United States, 77094
        • Recruiting
        • West Houston Area Clinical Trial Consultants, LLC
      • Houston, Texas, United States, 77036
        • Recruiting
        • Synergy Group Medical
      • McKinney, Texas, United States, 75071
        • Recruiting
        • Texas Institute of Cardiology PA
      • Missouri City, Texas, United States, 77459
        • Recruiting
        • Synergy Group Medical, LLC
      • Odessa, Texas, United States, 79761
        • Recruiting
        • Permian Research Foundation
      • Tyler, Texas, United States, 75701
        • Recruiting
        • Tyler Cardiovascular Consultants
    • Utah
      • Clinton, Utah, United States, 84015
        • Recruiting
        • Alpine Research TC
      • Provo, Utah, United States, 84604
        • Recruiting
        • Boeson Research PVU
    • Virginia
      • Manassas, Virginia, United States, 20109
        • Recruiting
        • Carient Heart & Vascular
      • Vienna, Virginia, United States, 22182
        • Recruiting
        • Conquest Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Key Inclusion Criteria:

  1. Has AF or flutter (paroxysmal or persistent), not considered to be secondary to a reversible cause, and an indication for indefinite anticoagulation treatment as described in the protocol

  2. Meets one of the following:

    1. CHA2DS2-VA [C: Congestive heart failure; H: Hypertension; A2: Age ≥75 years (double points); D: Diabetes mellitus; S2: Stroke or TIA or Systemic embolism (double points); V: Vascular disease; A: Age 65-74 years] score ≥2 and Oral Anticoagulant (OAC) naïve OR
    2. CHA2DS2-VA score ≥3 OR
    3. CHA2DS2-VA score of 2 AND at least 1 enrichment criteria as described in the protocol
  3. Must have an International Normalized Ratio (INR) <2.5 at the time of randomization if taking warfarin or another Vitamin K Antagonist (VKA)

Key Exclusion Criteria:

  1. Has a mechanical heart valve prosthesis (Note: transcatheter aortic valve replacement is not an exclusion)
  2. Has known moderate-to-severe mitral stenosis
  3. Has had a successful ablation therapy without documented recurrent AF or a participant after Left Atrial Appendage (LAA) occlusion/exclusion or plan for ablation or LAA occlusion/exclusion within the next 6 months starting from randomization
  4. Had an ischemic stroke within 2 days prior to randomization
  5. Has persistent, uncontrolled hypertension (per investigator's discretion)
  6. Has estimated Glomerular Filtration Rate (eGFR) <15 mL/min/1.73m2 within 30 days prior to randomization or is on dialysis or expected to be started on dialysis within the next 6 months starting from randomization

Note: Other protocol-defined Inclusion/ Exclusion criteria apply

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: REGN7508 + Placebo

Administered per the protocol

Administered per the protocol

Other Names:
  • cenvacibart
Active Comparator: Apixaban + Placebo

Administered per the protocol

Administered per the protocol

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type) or systemic embolism
Time Frame: Approximately 36 months
Approximately 36 months
Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding or ISTH Clinically Relevant Non-Major (CRNM) bleeding
Time Frame: Approximately 36 months
Approximately 36 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, ISTH major bleeding, or ISTH CRNM bleeding
Time Frame: Approximately 36 months
Approximately 36 months
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, or ISTH major bleeding
Time Frame: Approximately 36 months
Approximately 36 months
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, ISTH major bleeding, or all-cause death
Time Frame: Approximately 36 months
Approximately 36 months
Time to first occurrence of ISTH major bleeding
Time Frame: Approximately 36 months
Approximately 36 months
Time to first occurrence of hemorrhagic stroke, intracerebral hemorrhage, or hemorrhagic transformation of an ischemic stroke
Time Frame: Approximately 36 months
Approximately 36 months
Time to occurrence of fatal bleeding
Time Frame: Approximately 36 months
Approximately 36 months
Number of ISTH major bleeding events
Time Frame: Approximately 36 months
Approximately 36 months
Number of ISTH CRNM bleeding events
Time Frame: Approximately 36 months
Approximately 36 months
Number of minor bleeding events
Time Frame: Approximately 36 months
Approximately 36 months
Time to all-cause death
Time Frame: Approximately 36 months
Approximately 36 months
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Time Frame: Approximately 39 months
Approximately 39 months
Severity of TEAEs
Time Frame: Approximately 39 months
Approximately 39 months
Occurrence of Anti-Drug Antibodies (ADA) to REGN7508
Time Frame: Approximately 36 months
Approximately 36 months
Magnitude of ADA to REGN7508
Time Frame: Approximately 36 months
Approximately 36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Clinical Trial Management, Regeneron Pharmaceuticals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 10, 2026

Primary Completion (Estimated)

September 11, 2029

Study Completion (Estimated)

December 10, 2029

Study Registration Dates

First Submitted

May 29, 2026

First Submitted That Met QC Criteria

May 29, 2026

First Posted (Actual)

June 4, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 17, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • R7508-CVA-24114
  • 2025-521617-97-00 (Ctis)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

IPD Sharing Time Frame

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

IPD Sharing Access Criteria

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.